Last reviewed · How we verify
Rilpivirine (RPV)
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV-1 by binding to the reverse transcriptase enzyme.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the replication of HIV-1 by binding to the reverse transcriptase enzyme. Used for Treatment of HIV-1 infection in treatment-naive adults.
At a glance
| Generic name | Rilpivirine (RPV) |
|---|---|
| Also known as | Edurant |
| Sponsor | Janssen Infectious Diseases BVBA |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By binding to the reverse transcriptase enzyme, rilpivirine prevents the enzyme from converting viral RNA into DNA, thereby inhibiting viral replication. This mechanism of action is specific to HIV-1 and does not affect other viruses or cellular processes.
Approved indications
- Treatment of HIV-1 infection in treatment-naive adults
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Insomnia
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies (PHASE2)
- Antiviral Long Acting Drugs Landing in People Living With HIV (NA)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
- Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (NA)
- Combined Injectable Treatment for HIV and OUD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rilpivirine (RPV) CI brief — competitive landscape report
- Rilpivirine (RPV) updates RSS · CI watch RSS
- Janssen Infectious Diseases BVBA portfolio CI